Bill was CEO at Trovagene Inc., a precision oncology therapeutics and genetics company capitalizing on circulating tumor DNA in urine. Prior to Trovagene, Bill was President and Chief Executive Officer at Sequenom Inc. a leading molecular diagnostics company specializing in clinical applications of whole genomic sequencing for the reproductive health & oncology markets. While at Sequenom, Bill led the development and commercialization of first non-invasive prenatal test (NIPT) for detecting and accurately measuring fetal genomic DNA in mother’s blood and helped establish NIPT as the new global clinical standard for prenatal testing and a multibillion-dollar diagnostic market.